// App-Quantinova.ai

TPS1110 : Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).

Researchers

Presenter

  • Yukinori Ozaki

Principal Investigators

  • Koji Matsumoto

  • Masato Takahashi

  • Toru Mukohara

  • Manabu Futamura

  • Norikazu Masuda

  • Junji Tsurutani

  • Kenichi Yoshimura

  • Hironobu Minami

  • Toshimi Takano

Medical Centers

  • Toranomon Hospital, Tokyo, Japan

  • Hyogo Cancer Center, Hyogo, Japan

  • Hokkaido Cancer Center, Sapporo, Japan

  • Cancer Center, Kobe University Hospital, Kobe, Japan

  • Department of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  • National Hospital Organization, Nagoya, Japan

  • Kindai University Hospital, Osaka, Japan

  • Kyoto University, Kyoto, Japan

  • Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Human epidermal growth factor receptor 2

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Bevacizumab

  • Paclitaxel

  • Nivolumab

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • UMIN000030242

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved